Vectus Biosystems Limited · ASX:VBS
Vectus Biosystems — Shareholder Meeting (November 2025)
11 slides from Vectus Biosystems's shareholder meeting presentation, Nov 26, 2025
Slide 1: Chairman's Address to Vectus Biosystems Limited
ABN 54 117 526 137 Chairman’s Address to Vectus Biosystems Limited 26 November 2025 Annual General Meeting (AGM) It is my pleasure to provide the Chairman’s Address for the Company’s 2025 Annual General Meeting. As previously advised, Vectus has assembled a first-class team to support its commercial
Slide 2: Chairman's Address (continued)
ABN 54 117 526 137 that is in line with the needs of a broad range of pharmaceutical companies and potential collaborators. The Company continues to update its data room containing a broad portfolio of intellectual property (IP), data and information in relation to Vectus’ key assets as additional d
Slide 3: Annual General Meeting: Solutions for Unmet Medical Needs
ANNUAL GENERAL MEETING 26 November 2025 For personal use only Solutions for Unmet Medical Needs 1
Slide 4: Vectus Biosystems Limited Company Highlights
VECTUS BIOSYSTEMS LIMITED For personal use only Advanced Novel Peptide Therapeutic Treatments for Diseases with High Unmet Needs Publicly traded ASX:VBS Company Highlights • Robust clinical pipeline of fibrosis treatments for high unmet needs Established • Agreement with XORTX for US$3M in XORTX sha
Slide 5: Robust VIP Pipeline
Robust VIP Pipeline Preclinical IND Phase 1 Phase 2 For personal use only VB0004 Myocardial & Renal Fibrosis (including TTR-CM/CF) *Orphan Designation VB0004 Pulmonary Fibrosis VB4-A32 Liver Fibrosis Pulmonary Fibrosis, VB4-A79 Blood Pressure VB4-P5 ** Renal Antifibrotic *Orphan Indication ** Agreem
Slide 6: VB0004: Novel, First-In-Class VIP Agonist
VB0004: Novel, First- In-Class VIP Agonist For personal use only for Treatment of Myocardial & Renal Fibrosis Replenishing VIP in Tissue 4 6
Slide 7: C14 Consulting Group
AGM 26 November 2025 For personal use only C14 Consulting Group For the Business of Life Sciences Martina Molsbergen CEO, C14 Consulting Group www.c14consultingroup.com 5
Slide 8: C14 Exceptional Knowledge
Exceptional Knowledge Broad access to academia and industry For personal use only Business & Investment Strategy C14 is built on a large pedigree of former industry executives with proven track Deal Making records of success Scientific Evaluation 6
Slide 9: C14's Deal Making Success
C14's Deal Making Success Proven Track Record is Core Competence Plethora of deals spanning discovery, For personal use only clinical and commercial Out licensing focused (“sell” side), negotiations, transactions and strategic alliance management history Leverage C-level contacts within many Affilia
Slide 10: C14's Large Experience Base
C14's Large Experience Base For personal use only Life Science Sectors Therapeutic Areas Geographic Pharmaceuticals Cardiology Experience CNS Diagnostics Dermatology North America Immunology Immunology South America Biologics Infectious Disease Europe Vaccines Oncology Pain & Inflammatory Disease As
Slide 11: VB4-P5 Acquisition By XORTX (October 2025)
VB4-P5 Acquisition By XORTX (October 2025) For personal use only XORTX FOCUSED ON DEVELOPING INNOVATIVE ACQUISITION OF NOVEL NEW CHEMICAL ENTITY, USD $3.0 MILLION, PAYABLE IN COMMON SHARES THERAPIES TO TREAT GOUT AND PROGRESSIVE VB4-P5, ALONG WITH ITS ASSOCIATED OR COMMON SHARE EQUIVALENTS OF XORTX
Vectus Biosystems — Shareholder Meeting (November 2025) on 6ix